HOME - Luye Pharma Group

About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

On The Road

Patient Enrollment Completed for the Phase 3 Trial of Boan Biotech’s Aflibercept Intravitreous Injection in China

News

Yantai, March 13, 2023 - Luye Pharma Group today announced that patient enrollment has been completed for the Phase 3 clinical study (comparative clinical study of efficacy and safety) of BA9101 (Aflibercept Intravitreous Injection) in China. ...

March 13,2023

Luye Pharma Receives Clinical Trial Approval in Europe for Its Innovative Formulation Paliperidone Palmitate Long-acting Injection LY03010

Shanghai, February 23, 2023 - Luye Pharma Group today announced that it has received the approval by the competent authorities to initiate the first clinical trial in Europe for its Paliperidone Palmitate Prolonged Release Suspension for ...

February 23,2023

Boan Biotech’s Investigational Long-acting Anti-IL-4Rα Antibody BA2101 ...

Yantai, February 16, 2023 -- Luye Pharma Group today announced that BA2101, an investigational anti-IL-4Rα antibody developed by its subsidiary Boan Biotech, has been administered for the first patient in a Phase I clinical trial. Recognized as a Class 1 innovative biological product in China, BA2101 is the first long-acting anti-IL-4Rα monoclonal antibody that enters the clinical trial stage in the country. It is intended to be used for treating allergic diseases caused by Th2 inflammation, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and chronic spontaneous urticaria (CSU).

February 16,2023

Boan Biotech’s Investigational Anti-CD25 Antibody BA1106 Administered for ...

Yantai, February 13, 2023 – Luye Pharma Group today announced that BA1106, an investigational non-IL-2 blocking anti-CD25 antibody developed by its subsidiary Boan Biotech, has been administered for the first patient in a Phase I clinical trial. This trial is designed to evaluate the safety, pharmacokinetics and preliminary efficacy of BA1106 in patients with advanced solid tumors.

February 13,2023

Luye Pharma's 3-month Long-acting Goserelin Microspheres Approved for Clinical ...

Shanghai, January 30, 2023 — Luye Pharma Group today announced that its 3-month long-acting Goserelin Acetate Extended-release Microspheres for Injection (LY01022), an innovative anticancer formulation developed by the company itself, has been approved by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) for clinical trials, intended for treating prostate cancer and breast cancer that can be treated with hormones.

January 30,2023

Investors

July 19,2022

PHASE III CLINICAL TRIAL OF ROTIGOTINE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY03003) IN PARKINSON’S DISEASE MET PRIMARY ...

Stock Code:02186.HK

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company

Historic Breakthrough, Brand New Journey The Story of Rykindo® (LY03004) Approval in the U.S.

To Learn and Grow through Problem Discovery and Resolution Yu Fei Director of Analytical Research and Development, R&D Center, Luye Pharma

Learn the Best of the People around You Yan Yameng HR BP, Luye Pharma

What I think When I Run Andy Siow APAC Commercial Director, Luye Pharma (International)

To Practice with Every Opportunity Wang Chao Director of Engineering Department II, Shandong Luye

My Three Years with Luye US Antonia Sacchetti Office Manager, Luye Pharma (US)